Drug intelligence / Profile preview

chlorphenoxamine

Development stage: Discontinued
Lead developer: Dow
Modality: Small Molecules
Administration: Oral, Topical

Overview

Chlorphenoxamine is a first-generation ethanolamine antihistamine and anticholinergic agent, structurally related to diphenhydramine. It acts primarily as an H1 receptor antagonist (antihistaminic) and also exhibits antimuscarinic (anticholinergic) properties. Chlorphenoxamine has been used as an antipruritic for the treatment of itching, in hypersensitivity reactions, nausea, vomiting, vertigo, and was formerly used in the management of parkinsonism due to its central anticholinergic effects. Its mechanism involves blocking histamine H1 receptors to reduce allergic symptoms and exerting antimuscarinic activity that can help with movement disorders[1][2][4][6].

Brand names: Phenoxene

Targets

mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on chlorphenoxamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorphenoxamine.

Explore the full profile